Table 1.
Clinical characteristics | Year of diagnosis | |||
---|---|---|---|---|
Total | Cohort 1 (1986–2003) | Cohort 2 (2004–2015) | p-value | |
No. of patients | 418 (100) | 110 (26.3) | 308 (73.7) | |
Male sex | 318 (76.1) | 83 (75.5) | 235 (76.3) | 0.897 |
Age at diagnosis, median (IQR), yr | 22 (18–29) | 21 (17–27) | 23 (18–31) | 0.089 |
Age at diagnosis, yr | 0.072 | |||
≤16 (A1) | 56 (13.4) | 16 (14.6) | 40 (13.0) | |
17–40 (A2) | 324 (77.5) | 90 (81.8) | 234 (76.0) | |
>40 (A3) | 38 (9.1) | 4 (3.6) | 34 (11.0) | |
Interval from symptom onset to diagnosis, median (IQR), mo | 10.0 (3.2–35.0) | 14.8 (5.5–37.7) | 8.9 (2.6–29.8) | 0.005 |
Current smoking at diagnosis | 118 (28.2) | 34 (30.9) | 84 (27.3) | 0.537 |
Family history of IBD | 32 (7.7) | 9 (8.2) | 23 (7.5) | 0.835 |
Disease location at diagnosis | 0.525 | |||
Ileum (L1) | 104 (24.9) | 23 (20.9) | 81 (26.3) | |
Colon (L2) | 39 (9.3) | 10 (9.1) | 29 (9.4) | |
Ileocolon (L3) | 275 (65.8) | 77 (70.0) | 198 (64.3) | |
Upper GI involvement (L4) | 94 (22.5) | 19 (17.3) | 75 (24.4) | 0.144 |
Disease behavior at diagnosis | 0.814 | |||
Nonstricturing, nonpenetrating (B1) | 339 (81.1) | 91 (82.7) | 248 (80.5) | |
Stricturing (B2) | 34 (8.1) | 9 (8.2) | 25 (8.1) | |
Penetrating (B3) | 45 (10.8) | 10 (9.1) | 35 (11.4) | |
Perianal fistula before or at diagnosis | 181 (43.3) | 49 (44.5) | 132 (42.9) | 0.823 |
Duration of follow-up, median (IQR), mo | 123.7 (78.9–181.1) | 223.4 (200.1–256.3) | 100.8 (70.2–135.6) | <0.001 |
Ever use of medications | ||||
Systemic corticosteroids | 245 (58.6) | 83 (75.5) | 162 (52.6) | <0.001 |
Thiopurines | 340 (81.3) | 88 (80.0) | 252 (81.8) | 0.776 |
Methotrexate | 11 (2.6) | 3 (2.7) | 8 (2.6) | 0.645 |
Anti-TNF agents | 155 (37.1) | 46 (41.8) | 109 (35.4) | 0.251 |
Vedolizumab | 4 (1.0) | 3 (2.7) | 1 (0.3) | 0.058 |
Ustekinumab | 6 (1.4) | 2 (1.8) | 4 (1.3) | >0.999 |
Data are presented as number (%) unless otherwise indicated.
IQR, interquartile range; IBD, inflammatory bowel disease; GI, gastrointestinal; TNF, tumor necrosis factor.